Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants

Journal of Clinical Virology

Volumn 36, Issue 1, 2006, Pages 50-59

  Majerová Uhlíková, Tat'ána ^a,d   Dantuma, Nico P ^b   Lindsten, Kristina ^c   Masucci, Maria G ^c   Konvalinka, Jan ^a,d  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cell based assay; Drug resistant mutant; GFP; Green fluorescent protein; HIV PR; HIV protease; HIV proteinase

Indexed keywords

GREEN FLUORESCENT PROTEIN; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ARTICLE; DISEASE PREDISPOSITION; ENZYME INHIBITION; ENZYME KINETICS; EVALUATION; FLUORESCENCE ANALYSIS; FLUOROMETRY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE; ANTIBIOTIC RESISTANCE; BIOASSAY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; GENETICS; HELA CELL; KINETICS; METABOLISM; METHODOLOGY; MUTATION; PLASMID; REPORTER GENE; SPECTROPHOTOMETRY; VIRUS GENE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; EVALUATION STUDIES; FLOW CYTOMETRY; FLUOROMETRY; GENES, REPORTER; GENES, VIRAL; GREEN FLUORESCENT PROTEINS; HELA CELLS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; KINETICS; MICROSCOPY, FLUORESCENCE; MUTATION; PHENOTYPE; PLASMIDS; RECOMBINANT FUSION PROTEINS; SPECTROPHOTOMETRY; TRANSFECTION;

EID: 33744542380     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.01.014     Document Type: Article

References (35)

1. Barbaro G., Scozzafava A., Mastrolorenzo A., and Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11 14 (2005) 1805-1843
2. Beerenwinkel N., Schmidt B., Walter H., Kaiser R., Lengauer T., Hoffmann D., et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 99 (2002) 8271-8276
3. Bile E.C., Adje-Toure C., Borget M.Y., Kalou M., Diomande F., Chorba T., et al. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire. J Clin Virol 32 1 (2005) 60-66
4. Blair W.S., Isaacson J., Li X., Cao J., Peng Q., Kong G.F., et al. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antivir Res 65 2 (2005) 107-116
5. Blanco R., Carrasco L., and Ventoso I. Cell killing by HIV-1 protease. J Biol Chem 278 (2003) 1086-1093
6. Boucher C.W., Keulen T., Van Bommel M., Nijhuis D., De Jong M., De Jong P., et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 40 (1996) 2404-2409
7. Ceccherini-Silberstein F., Erba F., Gago F., Bertoli A., Forbici F., Bellocchi M.C., et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 18 12 (2004) F11-F19
8. de Mendoza C., Gallego O., and Soriano V. Mechanism of resistance to antiretroviral drugs - clinical implications. AIDS Rev 4 (2002) 64-82
9. Erickson J.W., and Burt S.K. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 36 (1996) 545-571
10. Gulnik S.V., Suvorov L.I., Liu B., Yu B., Anderson B., Mytsuya H., et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34 (1995) 9282-9287
11. Hertogs K., de Bethune M.P., Miller V., Ivens T., Schel P., Van Cauwenberge A., et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 (1998) 269-276
12. Holguin A., Paxinos E., Hertogs K., Womac C., and Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 31 3 (2004) 215-220
13. Jarmy G., Heinkelein M., Weissbrich B., Jassoy C., and Rethwilm A. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol 64 (2001) 223-231
14. Jacobsen H., Yasargil K., Winslow D.L., Craig J.C., Krohn A., Duncan I.B., et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206 (1995) 527-534
15. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 13 1 (2005) 51-57
16. Kellam P., and Larder B.A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 38 (1994) 23-30
17. Konvalinka J., Heuser A.M., Hruskova-Heidingsfeldova O., Vogt V.M., Sedlacek J., Strop P., et al. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases. Eur J Biochem 228 (1995) 191-198
18. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDS 4 (2004) 199-208
19. Lazdins J.K., Mestan J., Goutte G., Walker M.R., Bold G., Capraro H.G., et al. In vitro effect of alpha(1)-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 175 (1997) 1063-1070
20. Lindsten K., Uhlikova T., Konvalinka J., Masucci M.G., and Dantuma N.P. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother 45 (2001) 2616-2622
21. Lu J., and Kuritzkes D.R. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acq Immune Def Synd 27 (2001) 7-13
22. Mammano F., Trouplin V., Zennou V., and Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 74 (2000) 8231-8524
23. Nascimbeni M., Lamotte C., Peytavin G., Farinotti R., and Clavel F. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 43 11 (1999) 2629-2634
24. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42 (1998) 2637-2644
25. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44 4 (2000) 920-928
26. Richards A.D., Phylip L.H., Farmerie W.G., Scarborough P.E., Alvarez A., Dunn B.M., et al. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J Biol Chem 265 14 (1990) 7733-7736
27. Richman D.D. Benefits and limitations of testing for resistance to HIV drugs. J Antimicrob Chemother 53 4 (2004) 555-557
28. Rinnova M., Hradilek M., Barinka C., Weber J., Soucek M., Vondrasek J., et al. A picomolar inhibitor of resistant strains of human immunodeficiency virus protease identified by a combinatorial approach. Arch Biochem Biophys 382 1 (2000) 22-30
29. Sebastian J., and Faruki H. Update on HIV resistance and resistance testing. Med Res Rev 24 1 (2004) 115-125
30. Shafer R.W., Kantor R., and Gonzales M.J. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2 (2000) 211-228
31. Sham H.L., Kempf D.J., Molla A., Marsh K.C., Kumar G.N., Chen C.M., et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42 12 (1998) 3218-3224
32. Svicher V., Ceccherini-Silberstein F., Erba F., Santoro M., Gori C., Bellocchi M.C., et al. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 49 5 (2005) 2015-2025
33. Walter H., Schmidt B., Korn K., Vandamme A.M., Harrer T., and Uberla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 13 1/2 (1999) 71-80
34. Weber J., Mesters J.R., Lepsik M., Prejdova J., Svec M., Sponarova J., et al. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. J Mol Biol 324 4 (2002) 739-754
35. Williams J.W., and Morrison J.F. The kinetics of reversible tight-binding inhibition. Meth Enzymol 63 (1979) 437-467